Filter results

Tobacco Use clinical trials

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

View clinical trials related to Tobacco Use.

Filter by:

Not yet recruiting
« Prev · Page 2

NCT ID: NCT03040349 Not yet recruiting - Tobacco Use Clinical Trials

Tobacco Treatment TrAining Network in Greece & Cyprus

TiTAN

Start date: February 2017
Phase: N/A
Study type: Interventional

The overall aim of the TiTAN Greece & Cyprus project is to expand the Global Bridges Tobacco Treatment Training Network in the WHO Europe region through a focus on primary health care providers in Greece and Cyprus. A robust evaluation will be conducted alongside the TiTAN program. A pre-post evaluation will be used to examine the impact on the TiTAN program on: 1. Provider engagement (number of providers attending training), number of local champions; 2. Provider knowledge, beliefs, perceived behavioral control, and intentions related to the delivery of tobacco treatment; 3. Rates of evidence-based tobacco treatments (5As) are delivered to patients who smoke; 4. Provider satisfaction with training program, resources, and network outreach activity and areas for improvement; and 5. Estimates on the impact on patient-level outcomes including number of patient quit smoking at 1 and 3-month follow-up. All PHC providers will be surveyed before and after the intervention program is delivered. We will randomly select a sub-sample of providers and will survey patients from their practice before and after the intervention program in order to validate changes in 5As delivery. Qualitative interviews will be completed with a sub-sample of providers at the end of year 1.